NCT04016116

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Study of PD-1 Inhibition With Pemrolizumab Alore or Combined With JAK 2 Inhibition in Myeloproliferative Neoplasm and Hodgkin's Lymphoma

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Pembrolizumab will have significant clinical activity in patients with Intermediate and high risk MF, advanced PV who have been resistant, failed or are intolerant to JAK2 inhibitor therapy and the activity may be enhanced in combination with JAK2 inhibition by Ruxolitinib; similarly MDS/MPN and CMML patients for who no standard therapies are available will exhibit responses to PD-1 or dual JAK2 and PD-1 treatment. Adding JAK2 inhibitor Ruxolitinib to Pembrolizumab will have significant activity in patients with advanced, progressive HL who failed single agent PD-1 inhibition.

Conditions

• Cancer
• Hematological Malignancy

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab IV every 3 weeks
DRUG	Ruxolitinib	Ruxolitinib po days 1-21

Timeline

• Start date: 2019-12-01
• Primary completion: 2020-12-01
• Completion: 2021-12-01
• First posted: 2019-07-11
• Last updated: 2020-05-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study